| abstract |
The present invention relates to novel compounds, in particular novel pyridinones and derivatives thereof according to formula (I), all groups being specified in the application documents. The compounds according to the present invention are metabotropic receptor subtype 2 (“mGluR2” useful for treating or preventing glutamate dysfunction and neurological and psychiatric disorders associated with the mGluR2 subtype of the metabotropic receptor. )) Positive allosteric modulator. In particular, such diseases are central nervous system diseases selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The present invention is also directed to pharmaceutical compositions for the prevention and treatment of the above diseases involving mGluR2, methods of preparing the compounds and compositions, and uses of the compounds. |